tiprankstipranks
Advertisement
Advertisement
Allogene Therapeutics reports Q1 EPS (18c), consensus (18c)
PremiumThe FlyAllogene Therapeutics reports Q1 EPS (18c), consensus (18c)
16d ago
Allogene Highlights ALPHA3 Data and Extended Cash Runway
Premium
Company Announcements
Allogene Highlights ALPHA3 Data and Extended Cash Runway
16d ago
Allogene Therapeutics increases 2026 operating cash expense guidance
Premium
The Fly
Allogene Therapeutics increases 2026 operating cash expense guidance
16d ago
Allogene Therapeutics upgraded to Neutral from Underweight at JPMorgan
PremiumThe FlyAllogene Therapeutics upgraded to Neutral from Underweight at JPMorgan
1M ago
Allogene Therapeutics Prices Large Common Stock Offering
Premium
Company Announcements
Allogene Therapeutics Prices Large Common Stock Offering
1M ago
Allogene Therapeutics price target raised to $10 from $6 at Jefferies
Premium
The Fly
Allogene Therapeutics price target raised to $10 from $6 at Jefferies
1M ago
Allogene Therapeutics price target raised to $12 from $8 at H.C. Wainwright
PremiumThe FlyAllogene Therapeutics price target raised to $12 from $8 at H.C. Wainwright
2M ago
Allogene Therapeutics price target raised to $8 from $5 at Citizens
Premium
The Fly
Allogene Therapeutics price target raised to $8 from $5 at Citizens
2M ago
Cellectis highlights Allogene ALPHA3 trial data, potential milestone payments
Premium
The Fly
Cellectis highlights Allogene ALPHA3 trial data, potential milestone payments
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100